stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Alert me
Eli Lilly and Company (LLY) Free cash flow
Eli Lilly and Company's free cash flow for fiscal 2025 was $9.0B, up 138.6% from $3.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $18.2B. Over the past ten years it has ranged from $792.0M (fiscal 2023) to $9.0B (fiscal 2025) — the current reading is the highest in ten years. Eli Lilly and Company ranks 3rd of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $9.0B | 138.62% |
| FY2024 | $3.8B | 374.75% |
| FY2023 | $792.0M | (86.18%) |
| FY2022 | $5.7B | (5.36%) |
| FY2021 | $6.1B | 18.48% |
| FY2020 | $5.1B | 34.42% |
| FY2019 | $3.8B | (11.85%) |
| FY2018 | $4.3B | (4.96%) |
| FY2017 | $4.5B | 16.76% |
| FY2016 | $3.9B | 61.91% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $7.8B | 157.96% |
| Mar 2026 | $3.0B | 343.58% |
| Dec 2025 | $677.9M | (89.95%) |
| Sep 2025 | $6.7B | 385.47% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| JNJ Johnson & Johnson compare | $22.7B |
| ABBV AbbVie Inc. compare | $18.2B |
| LLY Eli Lilly and Company | $18.2B |
| MRK Merck & Co., Inc. compare | $16.1B |
| NVS Novartis AG compare | $15.2B |
| GILD Gilead Sciences, Inc. compare | $12.9B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement